While Nuvation Bio Inc has underperformed by -4.76%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NUVB fell by -17.29%, with highs and lows ranging from $3.97 to $1.54, whereas the simple moving average fell by -4.87% in the last 200 days.
On April 23, 2025, Citizens JMP started tracking Nuvation Bio Inc (NYSE: NUVB) recommending Mkt Outperform. A report published by Jefferies on March 27, 2024, Upgraded its rating to ‘Buy’ for NUVB. BTIG Research also Upgraded NUVB shares as ‘Buy’, setting a target price of $5 on the company’s shares in a report dated March 26, 2024. Jefferies January 06, 2023d the rating to Hold on January 06, 2023, and set its price target from $5 to $2. BTIG Research August 02, 2022d its ‘Buy’ rating to ‘Neutral’ for NUVB, as published in its report on August 02, 2022. BMO Capital Markets’s report from August 02, 2022 suggests a price prediction of $2.50 for NUVB shares, giving the stock a ‘Market Perform’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of Nuvation Bio Inc (NUVB)
To gain a thorough understanding of Nuvation Bio Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -119.66% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.01, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and NUVB is recording an average volume of 5.78M. On a monthly basis, the volatility of the stock is set at 10.69%, whereas on a weekly basis, it is put at 7.52%, with a gain of 5.26% over the past seven days. Furthermore, long-term investors anticipate a median target price of $7.86, showing growth from the present price of $2.2, which can serve as yet another indication of whether NUVB is worth investing in or should be passed over.
How Do You Analyze Nuvation Bio Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 33.54%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 48.25% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NUVB shares are owned by institutional investors to the tune of 48.25% at present.
